Arcturus Therapeutics Holdings (ARCT)
(Delayed Data from NSDQ)
$21.15 USD
+0.54 (2.62%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $21.17 +0.02 (0.09%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth C Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ARCT 21.15 +0.54(2.62%)
Will ARCT be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ARCT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ARCT
Here's Why Investors Should Invest in Arcturus Stock Now
New Strong Buy Stocks for September 13th
ARCT: What are Zacks experts saying now?
Zacks Private Portfolio Services
BioMarin Posts '27 Biz View, Outlines Growth Plans for Next 10 Years
Does Arcturus Therapeutics (ARCT) Have the Potential to Rally 216.35% as Wall Street Analysts Expect?
SNY's MS Drug Meets Goal in One Phase III Study; Misses in Two Others
Other News for ARCT
Arcturus Therapeutics: Strong Buy Rating on Vaccine Approval and Market Expansion Prospects
Biotech Alert: Searches spiking for these stocks today
Buy Rating Justified by Arcturus Therapeutics’s Vaccine Advancements and Market Expansion Potential
Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma
Japan?s Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics? Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma